Please login to the form below

Not currently logged in
Email:
Password:

Ischemix names David DeWahl as CEO

He joins the US biotech from private investment firm Colchester Healthcare Investments

David DeWahl has been appointed president and CEO of US biotech Ischemix.

He joins after stepping down from his role as president of private investment firm Colchester Healthcare Investments.

He has also previously served as VP corporate development at Helix Therapeutics and managing director at Life Science Group – a company he co-founded.

Prior to that, DeWahl was an investment banker with a focus on healthcare the life sciences.

“His background in building life sciences companies and his experience in developing corporate collaborations in the industry and in raising capital will substantially strengthen Ischemix as we continue the clinical development of our drug candidates,” said Dr Reinier Beeuwkes, chairman of the board and chief scientific officer at Ischemix.

These candidates include the company's lead compound CMX-2043, which is being developed to protect against heart and kidney damage due to the interruption of blood flow.

The investigational drug has recently demonstrated positive benefits in phase IIa trials, and further development is expected this year.

11th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics